EirGenix (TPE:6589) Piotroski F-Score: 4 (As of Jul. 05, 2026) — 33% Above Median


TPE:6589 EirGenix Inc TPE:6589
58 GF Score
Price NT$49.70
GF Value NT$92.26
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is EirGenix Piotroski F-Score?

EirGenix TPE:6589 +5.97% 58 Piotroski F-Score is 4 as of Jul. 05, 2026, which is 33% above its 10-year median of 3.00. GuruFocus rates TPE:6589 with a GF Score™ of 58/100 and a GF Value™ of NT$92.26 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,332 Biotechnology companies, EirGenix ranks better than 74.02% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

EirGenix has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for EirGenix's Piotroski F-Score or its related term are showing as below:

TPE:6589' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 5
Current: 4

During the past 13 years, the highest Piotroski F-Score of EirGenix was 5. The lowest was 1. And the median was 3.

EirGenix  (TPE:6589) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


EirGenix Piotroski F-Score Related Terms


EirGenix Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for EirGenix's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EirGenix Piotroski F-Score Chart

EirGenix Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 2.00 1.00 4.00 4.00

EirGenix Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 4.00 2.00 3.00 4.00

TPE:6589 vs VRTX, REGN, ALNY: Piotroski F-Score Comparison

For the Biotechnology subindustry, EirGenix's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EirGenix Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EirGenix's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where EirGenix's Piotroski F-Score falls into.


TPE:6589
58GF Score
EirGenix Inc TPE:6589
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was -157.094 + -370.763 + -60.313 + -172.382 = NT$-761 Mil.
Cash Flow from Operations was -111.754 + -168.942 + -34.807 + 613.513 = NT$298 Mil.
Revenue was 181.923 + 230.611 + 229 + 363.622 = NT$1,005 Mil.
Gross Profit was 17.16 + 18.398 + 32.538 + 125.733 = NT$194 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was
(10876.416 + 10767.858 + 10401.814 + 10397.463 + 10948.039) / 5 = NT$10678.318 Mil.
Total Assets at the begining of this year (Dec24) was NT$10,876 Mil.
Long-Term Debt & Capital Lease Obligation was NT$1,384 Mil.
Total Current Assets was NT$4,544 Mil.
Total Current Liabilities was NT$1,217 Mil.
Net Income was -104.015 + -220.617 + -256.118 + -117.594 = NT$-698 Mil.

Revenue was 219.693 + 246.403 + 248.223 + 294.641 = NT$1,009 Mil.
Gross Profit was 17.891 + 22.217 + 78.791 + 100.086 = NT$219 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was
(11162.559 + 11179.591 + 10927.201 + 10774.235 + 10876.416) / 5 = NT$10984.0004 Mil.
Total Assets at the begining of last year (Dec23) was NT$11,163 Mil.
Long-Term Debt & Capital Lease Obligation was NT$668 Mil.
Total Current Assets was NT$5,952 Mil.
Total Current Liabilities was NT$947 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

EirGenix's current Net Income (TTM) was -761. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

EirGenix's current Cash Flow from Operations (TTM) was 298. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=-760.552/10876.416
=-0.06992671

ROA (Last Year)=Net Income/Total Assets (Dec23)
=-698.344/11162.559
=-0.06256128

EirGenix's return on assets of this year was -0.06992671. EirGenix's return on assets of last year was -0.06256128. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

EirGenix's current Net Income (TTM) was -761. EirGenix's current Cash Flow from Operations (TTM) was 298. ==> 298 > -761 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=1384.146/10678.318
=0.1296221

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=667.766/10984.0004
=0.06079443

EirGenix's gearing of this year was 0.1296221. EirGenix's gearing of last year was 0.06079443. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=4544.207/1217.338
=3.73290491

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=5952.002/947.37
=6.28265831

EirGenix's current ratio of this year was 3.73290491. EirGenix's current ratio of last year was 6.28265831. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

EirGenix's number of shares in issue this year was 302.6. EirGenix's number of shares in issue last year was 305.976. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=193.829/1005.156
=0.19283474

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=218.985/1008.96
=0.21704032

EirGenix's gross margin of this year was 0.19283474. EirGenix's gross margin of last year was 0.21704032. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=1005.156/10876.416
=0.0924161

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=1008.96/11162.559
=0.09038788

EirGenix's asset turnover of this year was 0.0924161. EirGenix's asset turnover of last year was 0.09038788. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+0+1+0+0+1+0+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

EirGenix has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
EirGenix (TPE:6589) has a Piotroski F-Score of 4 as of Jul. 05, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on EirGenix and its competitors. This is 33% above median its historical median of 3.00. Over the past decade, EirGenix's Piotroski F-Score has ranged from 1.00 to 5.00. According to the industry distribution chart, EirGenix ranks #346 out of 1332 companies in the Biotechnology industry, placing it in the top 26%.
Is EirGenix's Piotroski F-Score too high?
EirGenix's current Piotroski F-Score of 4 is 33% above median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 5.00. The Biotechnology industry median Piotroski F-Score is 3.00. EirGenix's value of 4 is 33.3% above this industry median. Based on the distribution chart, EirGenix ranks #346 out of 1332 companies in the Biotechnology industry, which is above the industry midpoint. Overall, EirGenix has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does EirGenix's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, EirGenix ranks #346 out of 1332 companies for Piotroski F-Score. This puts EirGenix in the upper half of its industry. The industry median Piotroski F-Score is 3.00. EirGenix's value of 4 is 33.3% above this benchmark. Historically, EirGenix's own Piotroski F-Score has ranged from 1.00 to 5.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 3.00, EirGenix has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,332 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EirGenix's current Piotroski F-Score of 4 is 33.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on EirGenix and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EirGenix's current Piotroski F-Score is 4, which is 33% above median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EirGenix stock overvalued right now?
Based on GuruFocus' analysis, EirGenix (TPE:6589) is currently considered Possible Value Trap. The stock's GF Value™ is NT$92.26, compared to a current price of NT$49.70 — trading 46.1% below its estimated fair value. The current Piotroski F-Score is 4, which is 33% above median its 10-year median of 3.00 and 33.3% above the Biotechnology industry median of 3.00. EirGenix's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For EirGenix (TPE:6589), the current Piotroski F-Score is 4 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is EirGenix (TPE:6589) Overvalued in 2026?

Based on GuruFocus' analysis, EirGenix stock appears to be undervalued. The current stock price of NT$49.70 is trading 46.1% below its estimated GF Value™ of NT$92.26. GuruFocus considers EirGenix to be Possible Value Trap.

Key valuation signals for TPE:6589:

  • Piotroski F-Score: 4 (33% above median its 10-year median of 3.00)
  • GF Value™: NT$92.26 vs. price of NT$49.70 (46.1% below fair value)
  • GF Score™: 58/100 with 6 warning signs
  • Industry Position: 33.3% above the Biotechnology median (#346 of 1332)

No single metric tells the full story. See the TPE:6589 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


EirGenix Business Description

Address No. 101, Lane 169, Kangning Street, Xizhi District, New Taipei, TWN, 22180
EirGenix Inc is engaged in the research and development of biosimilars and new drugs, as well as biopharmaceutical contract development and manufacturing services, which included cell line construction platforms, process development platforms, analytical science and protein identification. Its products include CRM197 CARRIER PROTEIN, PRODUCT PIPELINE, COVID-19 ANTIGEN RAPID TEST. The revenue is derived from biopharmaceutical contract development and manufacturing services, sales of authorization and cooperative development, and sales of goods. Geographically, it operates in Japan, Taiwan, USA and Canada, Mainland China, Hong Kong, and Macao, and Europe, Others.
58GF Score

Get the complete analysis for TPE:6589

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$49.70
Price
NT$92.26
GF Value